The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Open accessAbstract
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the response of HER2 mutant cancers to HER2 inhibition varies depending on the tissue-of-origin of the cancer84”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [84]
In the citing paper
“In concordance with this, clinical testing of afatinib, neratinib, and dacomitinib achieved overall response rates of 8.7%, 9.5%, and 12%, respectively, for patients harboring EGFR or HER2 exon 20 mutations25,42,46,47.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 779
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
Krawczyk, P. A., Jassem, J., Wojas‐Krawczyk, K., Krzakowski, M. J., Dziadziuszko, R., & Olszewski, W. T. (2022) · Cancers · doi:10.3390/cancers14143429 · Cited by 13
Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis
Zhang, J., Han, W., Guo, J., Zhang, C., Cao, L., Peng, L., Han, X. W., & Wang, Z. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05509-0 · Cited by 12
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 14
Zeng, Z., & Zhu, Q. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382183 · Cited by 12
Site-agnostic biomarker-guided oncology drug development
Jørgensen, J. T. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1702521 · Cited by 12
Genetic analysis in the clinical management of biliary tract cancer
Wakai, T., Nagahashi, M., Shimada, Y., Prasoon, P., & Sakata, J. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12334 · Cited by 12
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
Andreatos, N., Iyer, G., & Grivas, P. D. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100179 · Cited by 12
Self-citationWu, Y., Ni, J., Chang, X., Zhang, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13480 · Cited by 12
PDCD4 limits prooncogenic neuregulin-ErbB signaling
Montero, J. C., & Pandiella, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03617-5 · Cited by 12
Koga, T., Suda, K., Nishino, M., Fujino, T., Ohara, S., Hamada, A., Soh, J., Tirunagaru, V. G., Vellanki, A., Doebele, R. C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-216 · Cited by 12
Veitch, Z. W. N., Ribnikar, D., Tilley, D. G., Tang, P. A., King, K. M., Bedard, P. L., Lupichuk, S., & Cescon, D. W. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01676-4 · Cited by 12
Application of histology-agnostic treatments in metastatic colorectal cancer
Bianchi, A. S., Agostara, A. G., Patelli, G., Mauri, G., Pizzutilo, E. G., & Siena, S. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.05.013 · Cited by 12
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 12
Convergent TP53 loss and evolvability in cancer
Mansur, M. B., & Greaves, M. F. (2023) · BMC Ecology and Evolution · doi:10.1186/s12862-023-02146-6 · Cited by 13
ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
Wilson, F. H., & Politi, K. A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0368 · Cited by 12
y Cajal, S. R., Hümmer, S., Peg, V., Matías‐Guiu, X., de Torres, I. M., Castellví, J., Martínez-Sáez, E. A., & Hernández‐Losa, J. (2019) · Histopathology · doi:10.1111/his.13828 · Cited by 12
Kinase activity of ERBB3 contributes to intestinal organoids growth and intestinal tumorigenesis
Nguyen, A. T., Lee, S., Chin, H. J., Le, Q. V.-C., & Lee, D. (2019) · Cancer Science · doi:10.1111/cas.14235 · Cited by 12
Kern, R., Corrêa, S., Scandolara, T. B., da Silva, J. C., Pires, B. R. B., & Panis, C. (2020) · Personalized Medicine · doi:10.2217/pme-2020-0070 · Cited by 13
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
Ni, J., & Zhang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312820 · Cited by 12
Molecular profiling in breast cancer—ready for clinical routine?
Tendl, K. A., & Bagó-Horváth, Z. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00578-0 · Cited by 12
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives
Filippi, R., Lombardi, P., Quarà, V., Fenocchio, E., Aimar, G., Milanesio, M. C., Leone, F., & Aglietta, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1667335 · Cited by 11
Blanc‐Durand, F., Camilleri, G. M., Bayle, A., Aldea, M. D., Vasseur, D., Ouali, K., Michels, J., Pautier, P., Nicotra, C., Ngo‐Camus, M., et al. (2024) · Cancer · doi:10.1002/cncr.35381 · Cited by 11
Liu, D., Jee, J., Drilon, A. E. D. C., Heilmann, A. M., Allen, J. M., Schrock, A. B., Keller-Evans, R. B., & Li, B. T. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0620 · Cited by 11
Self-citationAdvances in EGFR/HER2-directed clinical research on breast cancer
Chow, L. W., Lie, E. F., & Toi, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.009 · Cited by 11
Molecular Pathology of Breast Tumors
Ross, D. S., & Pareja, F. G. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.009 · Cited by 11
Клинический случай легочной формы мукормикоза у ребенка с острым лимфобластным лейкозом
Kharagezov, D. A., Lazutin, Y. N., Арменовна, М. Э., Milakin, A. G., Stateshny, O. N., Leyman, I. A., Васильевна, Ч. А., & Дмитриевич, И. К. (2021) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2021-2-4-5 · Cited by 11
Berlin, J. D., Tolcher, A. W., Ding, C., Whisenant, J. G., Horak, I. D., Wood, D. L., Nadler, P. I., Hansen, U. H., Lantto, J., Skartved, N. J. Ø., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01217-7 · Cited by 11
Salawu, A., Hansen, A. R., Spreafico, A., Al-Ezzi, E. M., Webster, S., Bedard, P. L., Doi, J., Wang, L. E., Siu, L. L., & Razak, A. R. A. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00884-z · Cited by 11
Lu, B., Liu, Y., Yao, Y., Zhu, D., Zhang, X., Dong, K., Xu, X., Lv, D., Zhao, Z., Zhang, H., et al. (2024) · Biology Direct · doi:10.1186/s13062-024-00516-8 · Cited by 11
Nakamura, Y., Shitara, K., & Lee, J. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321247 · Cited by 11
Rodríguez-Freixinós, V., Lheureux, S., Mandilaras, V., Clarke, B. A., Dhani, N. C., MacKay, H. J., Butler, M. O., Wang, L., Siu, L. L., Kamel‐Reid, S., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.02.005 · Cited by 11
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Chen, Z., Tang, X., Eichholz, J., McPherson, A., Thomas, J., Nagar, K. K., Rustgi, N., Christin, J. R., Kuo, F., Gao, S. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67643-2 · Cited by 11
Self-citationYang, L., Li, Y., Du, Y. E., Guo, Y., Guo, Z., Liu, B., Liu, J., Liu, Y., Niu, H., Sun, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02302 · Cited by 10
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao, W., Rajendran, B. K., Cui, T., Sun, J., Yingchun, Z., Palaniyandi, T., & Selvam, M. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5447 · Cited by 10
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers
Lee, E. K., Kolin, D. L., Matulonis, U. A., & Erickson, B. K. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.03.011 · Cited by 12
Huang, C., Yeh, Y., Cheng, H.-F., Chen, B.-F., Liu, C., Tsai, Y., Ho, H., & Tseng, L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001258 · Cited by 10
Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report
Inagaki, C., Maeda, D., Kimura, A., Otsuru, T., Iwagami, Y., Nishida, N., Sakai, D., Shitotsuki, R., Yachida, S., Doki, Y., et al. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i9.761 · Cited by 10
Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
Wagner, A., Galicia‐Andrés, E., Teufl, M., Gold, L., Obinger, C., Sykacek, P., Oostenbrink, C., & Traxlmayr, M. W. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00384 · Cited by 10
Targeting human EGFR 2 (HER2) in salivary gland carcinoma
Wotman, M. T., El‐Naggar, A. K., & Ferrarotto, R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2208350 · Cited by 10
Cell death in cancer in the era of precision medicine
Raschellà, G., Melino, G., & Gambacurta, A. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0048-6 · Cited by 10
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Kunos, C. A., Capala, J., Kohn, E. C., & Ivy, S. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00560 · Cited by 10
Chiang, N., Chen, L., Shan, Y., Yeh, C., & Chen, M. (2021) · Biomolecules · doi:10.3390/biom11010097 · Cited by 10
Jackisch, C., Barcenas, C. H., Bartsch, R., Palma, J. D., Glück, S., Harbeck, N., Macedo, G., O’Shaughnessy, J., Pistilli, B., Ruíz‐Borrego, M., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.02.001 · Cited by 10
Mohanty, S. K., Mishra, S. K., Tiwari, A. K., Sharma, S., Bhardwaj, M., Pattnaik, N., Jaiswal, S. K., Baisakh, M. R., Das, S., Pradhan, M. R., et al. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab083 · Cited by 10
The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis
Zhou, N., Zhao, J., Huang, X. Y., Shen, H., Li, W., Xu, Z., & Xia, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.04.09 · Cited by 10
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group
D’Ambrosio, L., Sbaraglia, M., Merlini, A., Rabino, M., Grignani, G., Appolloni, V., Badalamenti, G., Baldi, G. G., Bellan, E., Benelli, M., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104960 · Cited by 9
Fu, Z., Song, Y., Liu, F., Chen, L., Cai, S., Cui, P., Wang, G., Xie, W., Zhang, S., Ding, L., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.014 · Cited by 9
Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine
Lengyel, C. G., Habeeb, B. S., Khan, S. Z., Bairi, K. E., Altuna, S. C., Hussain, S., Mazher, S. A., Trapani, D., & Petrillo, A. (2020) · Gastrointestinal Disorders · doi:10.3390/gidisord3010001 · Cited by 9
Bayesian sample size determination in basket trials borrowing information between subsets
Zheng, H., Grayling, M. J., Mozgunov, P., Jaki, T., & Wason, J. M. S. (2022) · Biostatistics · doi:10.1093/biostatistics/kxac033 · Cited by 9
Wang, Z., Gao, L., Jia, Z., Liu, L., Gu, A., Liu, Z., Zhu, Q., Zuo, Y., Yang, M., Wang, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02150-w · Cited by 10
Westermann, L., Olivier, A. C., Samel, C., Eysel, P., Herren, C., Sircar, K., & Zarghooni, K. (2019) · Acta Neurochirurgica · doi:10.1007/s00701-019-04115-9 · Cited by 9
Nivolumab: an investigational agent for the treatment of biliary tract cancer
Federico, A. D., Rizzo, A., Ricci, A. D., Frega, G., Palloni, A., Tavolari, S., & Brandi, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1863946 · Cited by 9
Han, B., Gu, Z., Liu, Z., & Ling, H. (2022) · Cancer Management and Research · doi:10.2147/cmar.s346319 · Cited by 9
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes
Dong, X., Huang, D., Yi, X., Zhang, S., Wang, Z., Yan, B., Sham, P. C., Chen, K., & Li, M. J. (2020) · Communications Biology · doi:10.1038/s42003-019-0736-4 · Cited by 9
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Corné, J., Quillien, V., Godey, F., Cherel, M., Cochet, A., Du, F. L., Robert, L., Bourien, H., Brunot, A., Crouzet, L., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13592 · Cited by 8
Pu, X., Li, L., Xu, F., Wang, Z., Fu, Y. S., Wu, H., Ren, J., Chen, J., & Sun, B. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05894-0 · Cited by 8
Self-citationCiciriello, F., Pezzicoli, G., Biasi, A., D’Addario, C., Salonne, F., Porta, C., & Rizzo, M. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01165-1 · Cited by 8
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer
Chaubal, R., Talker, E., Chitra, J., Kadam, R., Gardi, N., Ursekar, R., Kadam, A., Singh, A., Sale, S., Pandey, S., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07759-7 · Cited by 8
Shan, J., Ruan, J., Tan, Y., Li, Y., Chen, S., Du, M., & Wang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s271999 · Cited by 8
Nishio, S. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15578 · Cited by 8
Yang, Y., Yang, G., Li, W., Hao, X., Zhang, S., Ai, X., Lei, S., Xu, H., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15118 · Cited by 8
Raei, M., Heydari, K., Tabarestani, M., Razavi, A., Mirshafiei, F., Esmaeily, F., Taheri, M., Hoseini, A., Nazari, H., Shamshirian, D., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12674-z · Cited by 10
Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape
Awosika, J. A., Monge, C., & Greten, T. F. (2024) · Hepatic Oncology · doi:10.1080/20450923.2024.2403334 · Cited by 8
Huang, X. Y., Jin, R., Lou, L., Zhao, J., Xia, L., Zhao, J., Li, W., Xu, Z., & Xia, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-2759 · Cited by 8
Bayesian basket trial design with false-discovery rate control
Zabor, E. C., Kane, M. J., Roychoudhury, S., Nie, L., & Hobbs, B. P. (2022) · Clinical Trials · doi:10.1177/17407745211073624 · Cited by 8
Current and future therapies for targeting HER2 mutations in gastrointestinal cancer
Dika, I. E., & Ilson, D. H. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1510324 · Cited by 8
Geiersbach, K. B., Chen, H., Emmadi, R., Haskell, G., Lu, X., Liu, Y. J., & Swisshelm, K. L. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.02.002 · Cited by 8
Rachiglio, A. M., Sacco, A., Forgione, L., Esposito, C., Chicchinelli, N., & Normanno, N. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00004 · Cited by 9
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine
Iyer, P., Chen, M., Goyal, L., & Denlinger, C. S. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2019.12.11 · Cited by 8
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
Oliveira, M., Garrigós, L., Assaf, J. D., Escrivá-de-Romaní, S., & Saura, C. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1807947 · Cited by 8
Self-citationMolecular Mechanisms of Endocrine Resistance
Fu, X., Angelis, C. D., Veeraraghavan, J., Osborne, C. K., & Schiff, R. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-99350-8_11 · Cited by 8
Piha-Paul, S. A., Tseng, C., Tran, H. T., Gao, M., Karp, D. D., Subbiah, V., Tsimberidou, A. M., Kawedia, J. D., Fu, S., Pant, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04545-4 · Cited by 7
Self-citationLiu, C., Li, T., Cui, X., Lv, Y., Liu, M., Zhou, X., Yang, F., Dong, Y., Li, R., Zhang, F., et al. (2025) · Cancer Control · doi:10.1177/10732748251347572 · Cited by 7
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
Peptide-Based Targeted Covalent Inhibitors
Cao, F., Guo, R.-C., Zhang, Z., & Yu, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18100 · Cited by 8
Liu, J., Zhuo, Y., Wang, F., Li, Z., Lin, Y., Li, L., Pan, J., Song, Y., Du, H., Li, C., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s321655 · Cited by 7
Tian, H., Qu, M., Zhang, G., Yuan, L., Shi, Q., Wang, Y., Yang, Y., Zhang, Y., & Qi, X. (2023) · The Oncologist · doi:10.1093/oncolo/oyad122 · Cited by 7
Conformational diversity and protein–protein interfaces in drug repurposing in Ras signaling pathway
Sayin, A. Z., Abali, Z., Senyuz, S., Cankara, F., Gürsoy, A., & Keskin, Ö. (2024) · Scientific Reports · doi:10.1038/s41598-023-50913-8 · Cited by 7
Yang, G., Liu, R., Li, P., Yang, Y., Wang, Y., Mao, H., & Tang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01154-2 · Cited by 7
Mondaca, S., Walch, H. S., Sepúlveda, S. A., Schultz, N. D., Muñoz, G., Yaqubie, A., Macanas-Pirard, P., Pareja-Barrueto, C., Garcia, P., Chatila, W. K., et al. (2024) · JCO Global Oncology · doi:10.1200/go.24.00090 · Cited by 7
Self-citationZhou, Q., Hou, C.-N., Yang, H.-J., He, Z., & Zuo, M. (2018) · Cancer Management and Research · doi:10.2147/cmar.s183769 · Cited by 7
Molecular Targets Beyond the Big 3
Reckamp, K. L. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.004 · Cited by 7
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Grill, S., & Klein, E. (2021) · Breast Care · doi:10.1159/000513800 · Cited by 7
Huang, H., Wang, Z., Li, Y., Zhao, Q., & Niu, Z. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-47 · Cited by 7
Kaizer, A. M., Zabor, E. C., Nie, L., & Hobbs, B. P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272367 · Cited by 7
Piha-Paul, S. A., Azaro, A., Arkenau, H., Oh, D., Galsky, M. D., Pal, S. K., Hamada, K., He, Y., Yamamiya, I., Benhadji, K. A., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01104-7 · Cited by 7
Self-citationLüftner, D., Tesch, H., Schmidt, M., Hartkopf, A. D., Streicher, S., Resch, A., Genovese, L., Rosé, C., Valenti, R., & Harbeck, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.045 · Cited by 7
Annaratone, L., Sarotto, I., & Marchiò, C. (2018) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_4710-1 · Cited by 7
CHRONIC FISTULA OF THE MANDIBLE.
NEWBY, J. D., & AITKEN, W. J. (1964) · PubMed Central · Cited by 7
Hoe, H. J., & Solomon, B. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01768 · Cited by 7
Vandekerkhove, G. R., Murtha, A. J., Müller, D. C., Stephenson, M., Rostin, K., Munzur, A. D., Vasquez-Rios, C., Nikkola, J., Sipola, J., Annala, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3912 · Cited by 6
Variant calling enhances the identification of cancer cells in single-cell RNA sequencing data
Gasper, W., Rossi, F., Ligorio, M., & Ghersi, D. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010576 · Cited by 7
Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain
Bang, I., Hattori, T., Leloup, N. O. L., Corrado, A. D., Nyamaa, A., Koide, A., Geles, K. G., Buck, E. A., & Koide, S. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01751-w · Cited by 8
Lin, L., Ge, H., Yan, Z., Wang, G., Wu, X., & Lv, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s228726 · Cited by 6
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Bueno, C., Martín, M., del Monte-Millán, M., García-Sáenz, J. Á., & López‐Tarruella, S. (2022) · Cancers · doi:10.3390/cancers14030512 · Cited by 6
Zhuo, X., Guo, H., Ma, J., Lai, J., Liu, L., Yin, K., Zhao, J., Wang, J., Jiang, F., Xu, W., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04196-7 · Cited by 6
Chowdhury, M. A. N., Wang, S., Suen, C., Hwang, M., Hsueh, Y.-A., & Shieh, S.-Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05077-0 · Cited by 6
Velaga, R., Tanaka, S., & Toi, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.10 · Cited by 6
Mendeville, M., Roemer, M. G. M., Vries, G. T. L.-D., Chamuleau, M. E. D., de Jong, D., & Ylstra, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.970063 · Cited by 6
Metadata
- Authors
- Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Dana-Farber Cancer Institute (US)
- USC Norris Comprehensive Cancer Center (US)
- Vanderbilt University (US)
- Peter MacCallum Cancer Centre (AU)
- Washington University in St. Louis (US)
- Puma Biotechnology (United States) (US)
- Corresponding author
- Hyman, David M.
- ORCID
- Hyman, David M.
- Piha-Paul, Sarina A.
- Won, Helen
- Rodon, Jordi
- Saura, Cristina
- Shapiro, Geoffrey I.
- Juric, Dejan
- Quinn, David I.
- Mayer, Ingrid A.
- Boni, Valentina
- Calvo, Emiliano
- Loi, Sherene
- Lockhart, Albert C.
- Erinjeri, Joseph P.
- Scaltriti, Maurizio
- Ulaner, Gary A.
- Patel, Juber
- Bouvier, Nancy
- Murali, Rajmohan
- Schram, Alison M.
- Smyth, Lillian M.
- Jhaveri, Komal
- Li, Bob T.
- Drilon, Alexander
- Harding, James J.
- Iyer, Gopa
- Taylor, Barry S.
- Berger, Michael F.
- Xu, Feng
- Eli, Lisa D.
- Lalani, Alshad S.
- Bryce, Richard P.
- Arteaga, Carlos L.
- Solit, David B.
- Venue
- Nature
- Published
- 2018-01-31
- Volume
- 554
- Issue
- 7691
- Pages
- 189-194
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5808581
- OpenAlex
- W2785610956
- Cited by
- 780
- References
- 54
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-02-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Puma Biotechnology
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
